

Key Business Highlights

- ❖ Focus on building on the financial momentum, expanding the base business and increasing facility throughput
- ❖ Throughout the COVID-19 crisis, the Company's GMP pharmaceutical manufacturing facilities and laboratories have remained fully operational and business operations have continued with minimal disruption
- ❖ IDT received formal correspondence from the U.S. Food and Drug Administration that it had lifted the Company's Warning Letter, restoring the Company's facility status
- ❖ IDT executing on its Medicinal Cannabis Manufacturing Plan
 - First commercial scale batches of solvent extracted GMP medicinal cannabis resin
 - First GMP medicinal cannabis oil-in-bottle batches produced
- ❖ COVID-19 Response and Australian Sovereign Pharmaceutical Manufacturing
 - IDT assisted in the Australian Government's initial COVID-19 response effort
 - Several submissions made to the Federal Government advocating for increased Australian sovereign pharmaceutical manufacturing
 - IDT has responded to the Australian Government's COVID-19 Vaccine and Treatment Manufacture and Supply Chain Request for Information

Key Financial Highlights



Year ended 30 June ('\$000)	2020	2019	Variance	
<i>Results from operations including one time adjustments*</i>				
Revenue	14,169	12,130	2,039	↑ 17%
EBITDA	788	(3,601)	4,389	↑ 122%
NPAT	(1,919)	(6,083)	4,164	↑ 68%
Basic earnings per share	(0.8¢)	(2.5¢)	1.7¢	↑ 68%

- ❖ Year-on-year Revenue growth of 17% to \$14.2 million (which includes \$0.9 million previously capitalised milestone)
- ❖ Positive EBITDA achieved for full year 2020 which represents a year-on-year improvement of 122%*
- ❖ Cost containment initiatives deliver a year-on-year reduction of \$0.6 million in Operational Expenses
- ❖ Strong cash balance of \$6.9 million

